Literature DB >> 2737235

Effect of neostigmine on metoclopramide-induced aldosterone secretion in man.

D K Sommers1, E C Meyer, M van Wyk.   

Abstract

This study examines the role of a neostigmine-induced increase in acetylcholine on the aldosterone stimulating effect of metoclopramide. Six normal male volunteers received the following three treatments in a cross-over randomized sequence: neostigmine, 0.5 mg s.c.; metoclopramide 10 mg i.v.; and neostigmine 0.5 mg s.c., followed by metoclopramide 10 mg i.v. Metoclopramide increased serum aldosterone significantly to 161% of basal level at 15 min. With neostigmine aldosterone levels peaked (129%) significantly at 30 min. In the presence of neostigmine, however, the metoclopramide-induced aldosterone response was blunted significantly. These results would suggest that presynaptic autoreceptors depresses the continued output of acetylcholine, thereby blunting the aldosterone responses to metoclopramide significantly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737235     DOI: 10.1007/bf00558305

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Aldosterone response to metoclopramide is mediated through the autonomic nervous system in man.

Authors:  D K Sommers; E C Meyer; M van Wyk; L S de Villiers
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Peripheral dopamine receptor identification: properties of a specific dopamine receptor in the rat adrenal zona glomerulosa.

Authors:  M G Dunn; H B Bosmann
Journal:  Biochem Biophys Res Commun       Date:  1981-04-30       Impact factor: 3.575

3.  Adrenal sensitivity to angiotensin II and undiscovered aldosterone stimulating factors in hypertension.

Authors:  R D Brown; M Wisgerhof; P C Carpenter; G Brown; N S Jiang; P Kao; R Hegstad
Journal:  J Steroid Biochem       Date:  1979-07       Impact factor: 4.292

4.  Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition.

Authors:  A G Dupont; P Vanderniepen; J J Smitz; R O Six
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

6.  Gastrointestinal effects of metoclopramide in man. In vitro experiments with human smooth muscle preparations.

Authors:  M Eisner
Journal:  Br Med J       Date:  1968-12-14

7.  The role of adrenal medulla in endogenous dopaminergic inhibition of aldosterone secretion.

Authors:  E Jungmann; G Germann; I Austin; B Mack; D Storp-Wenke; W Fassbinder; U Schwedes; K H Usadel; A Encke; K Schöffling
Journal:  Res Exp Med (Berl)       Date:  1986

8.  Effect of ganglionic blockade with trimethaphan on corticosteroid responses to metoclopramide in rhesus monkeys.

Authors:  J R Sowers; F W Beck; P Eggena
Journal:  J Hypertens       Date:  1984-08       Impact factor: 4.844

9.  Dopaminergic regulation of 18-hydroxycorticosterone and aldosterone secretion in man.

Authors:  J R Sowers; F W Beck
Journal:  Acta Endocrinol (Copenh)       Date:  1983-02

10.  Pharmacological analysis of the effects of metoclopramide on the guinea pig isolated stomach.

Authors:  A M Hay
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

  10 in total
  1 in total

1.  The effect of neostigmine on metoclopramide-induced aldosterone secretion after the administration of muscarinic antagonists in man.

Authors:  D K Sommers; E C Meyer; M van Wyk
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.